Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jay Achar

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
The Lancet. Infectious Diseases|June 16, 2024
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort studyOleksandr Korotych, Jay Achar, Elmira Gurbanova, et al.
Emerging Infectious Diseases|February 22, 2019
Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant TuberculosisMuhammad Osman, Elizabeth P Harausz, Anthony J Garcia-Prats, et al.
PLOS Global Public Health|April 28, 2023
Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effectiveCarly A Rodriguez, Sara Lodi, C Robert Horsburgh, et al.
Emerging Infectious Diseases|January 27, 2016
Prognostic Indicators for Ebola Patient SurvivalSamuel J Crowe, Matthew J Maenner, Solomon Kuah, et al.
The European Respiratory Journal|December 22, 2019
Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosisSyed Abidi, Jay Achar, Mourtala Mohamed Assao Neino, et al.
The Lancet. Infectious Diseases|October 2, 2025
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosisJames A Seddon, Jay Achar, Amyn A Malik, et al.
Plos Medicine|July 12, 2018
Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysisElizabeth P Harausz, Anthony J Garcia-Prats, Stephanie Law, et al.
The Lancet. Child & Adolescent Health|January 24, 2025
Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysisAnthony J Garcia-Prats, Maria Garcia-Cremades, Vivian Cox, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
The Lancet. Infectious Diseases|June 16, 2024
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort studyOleksandr Korotych, Jay Achar, Elmira Gurbanova, et al.
Emerging Infectious Diseases|February 22, 2019
Treatment Outcomes in Global Systematic Review and Patient Meta-Analysis of Children with Extensively Drug-Resistant TuberculosisMuhammad Osman, Elizabeth P Harausz, Anthony J Garcia-Prats, et al.
PLOS Global Public Health|April 28, 2023
Comparative effectiveness of adding delamanid to a multidrug-resistant tuberculosis regimen comprised of three drugs likely to be effectiveCarly A Rodriguez, Sara Lodi, C Robert Horsburgh, et al.
Emerging Infectious Diseases|January 27, 2016
Prognostic Indicators for Ebola Patient SurvivalSamuel J Crowe, Matthew J Maenner, Solomon Kuah, et al.
The European Respiratory Journal|December 22, 2019
Standardised shorter regimens <i>versus</i> individualised longer regimens for rifampin- or multidrug-resistant tuberculosisSyed Abidi, Jay Achar, Mourtala Mohamed Assao Neino, et al.
The Lancet. Infectious Diseases|October 2, 2025
Management of individuals exposed to multidrug-resistant or rifampicin-resistant tuberculosisJames A Seddon, Jay Achar, Amyn A Malik, et al.
Plos Medicine|July 12, 2018
Treatment and outcomes in children with multidrug-resistant tuberculosis: A systematic review and individual patient data meta-analysisElizabeth P Harausz, Anthony J Garcia-Prats, Stephanie Law, et al.
The Lancet. Child & Adolescent Health|January 24, 2025
Characteristics of children and adolescents with multidrug-resistant and rifampicin-resistant tuberculosis and their association with treatment outcomes: a systematic review and individual participant data meta-analysisAnthony J Garcia-Prats, Maria Garcia-Cremades, Vivian Cox, et al.
Pageof 4